Trump Administration's Medicaid Drug Price Promise Faces Delays and Uncertainties
The Trump administration's promise to lower drug prices in Medicaid through 'most-favored-nation' deals with pharmaceutical companies is facing significant delays and uncertainties. President Trump had announced in September of last year that companies like Pfizer would offer all their prescription medications to Medicaid at these discounted prices, expecting a substantial reduction in costs. However, NPR pharmaceuticals correspondent Sydney Lupkin reports that neither Pfizer nor 16 other major drug companies have confirmed that all their drugs would be discounted, nor have they specified the number of discounted drugs. The federal agency overseeing Medicaid also declined to provide this information. The initiative is structured as a voluntary pilot program, requiring each state to opt-in and agree to specific conditions, but the ramp-up has been slow, with states now having until September 30 to sign binding agreements.
